{
    "id": "5c915e51ecadf2e73f00000c",
    "question": "Can prevnar 13 be used in children?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the relevant documents and their information about the pneumococcal conjugate vaccine (Prevnar 13) in children. According to Document [1] and [2], Prevnar 13 is a recommended vaccine for children, and it is administered as a series of doses starting at 12 months of age. However, the question asks if Prevnar 13 can be used in children, but does not specify the age. Document [3] mentions that the conjugate pneumococcal vaccine (Prevnar 13) followed by the 23-valent polysaccharide vaccine (Pneumovax) is recommended for adults, but it does not provide information about the use of Prevnar 13 in children. Document [4] states that Prevnar 13 is recommended for the elderly and younger immunocompromised patients. Since the question does not specify the age group, we need to consider the general information provided in the documents. Given that Prevnar 13 is a conjugate vaccine and is generally recommended for children, the answer is likely yes, but we need to consider the age range. According to Document [1] and [2], Prevnar 13 is administered starting at 12 months of age, so it can be used in children over 12 months old. However, the question does not specify the upper age limit, and Document [4] does not provide information about the use of Prevnar 13 in children older than 12 months. Therefore, the most accurate answer is that Prevnar 13 can be used in children over 12 months old, but the exact age range is not specified in the documents. Based on the available information, the answer is that Prevnar 13 can be used in children over 12 months old, but the exact age range is not specified. However, since the options are yes or no, and considering that Prevnar 13 can be used in children over 12 months old, the best answer is\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_11434",
            "title": "InternalMed_Harrison",
            "content": "In the absence of compelling data as to optimal timing, it is reasonable to administer the pneumococcal and H. influenzae type b conjugate vaccines to both autologous and allogeneic HSC transplant recipients beginning 12 months after transplantation. A series that includes both the 13-valent pneumococcal conjugate vaccine (Prevnar) and the 23-valent pneumococcal polysaccharide vaccine (Pneumovax) is now recommended (according to CDC guidelines). The pneumococcal and"
        },
        {
            "id": "Pediatrics_Nelson_2074",
            "title": "Pediatrics_Nelson",
            "content": "6a. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks) Routine vaccination: \u007f Administer a series of PCV13 vaccine at ages 2, 4, 6 months with a booster at age 12 through 15 months. \u007f For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). Catch-up vaccination: \u007f Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age. \u007f For other catch-up issues, see Figure 2. Vaccination of persons with high-risk conditions: \u007f For children aged 24 through 71 months with certain underlying medical conditions (see footnote 6c), administer 1 dose of PCV13 if 3 doses of PCV were received previously, or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously. \u007f A single dose of PCV13 may be administered to previously unvaccinated children aged 6 through 18"
        },
        {
            "id": "Pediatrics_Nelson_2043",
            "title": "Pediatrics_Nelson",
            "content": "6a. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks) Routine vaccination: \u007f Administer a series of PCV13 vaccine at ages 2, 4, 6 months with a booster at age 12 through 15 months. \u007f For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). Catch-up vaccination: \u007f Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age. \u007f For other catch-up issues, see Figure 2. Vaccination of persons with high-risk conditions: \u007f For children aged 24 through 71 months with certain underlying medical conditions (see footnote 6c), administer 1 dose of PCV13 if 3 doses of PCV were received previously, or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously. \u007f A single dose of PCV13 may be administered to previously unvaccinated children aged 6 through 18"
        },
        {
            "id": "InternalMed_Harrison_9906",
            "title": "InternalMed_Harrison",
            "content": "Because of the increased risk of infections due to Streptococcus pneumoniae and other bacterial pathogens that cause pneumonia after influenza, the conjugate pneumococcal vaccine (Prevnar 13) followed by the 23-valent polysaccharide vaccine (Pneumovax) as well as influenza vaccine should be administered. The estimated rates of response to influenza vaccine are >80% among persons with asymptomatic HIV infection and <50% among those with AIDS. In general, live attenuated vaccines are contraindicated for persons with immune dysfunction. Because measles (rubeola) can be a severe or lethal infection in HIV-positive patients, these patients should receive the measles vaccine (or the combination MMR vaccine) unless the CD4+ T cell count is <200/\u03bcL. Between 18% and 58% of symptomatic HIV-infected vaccinees develop adequate measles antibody titers, and 50\u2013100% of asymptomatic HIV-infected persons seroconvert."
        },
        {
            "id": "InternalMed_Harrison_10162",
            "title": "InternalMed_Harrison",
            "content": "A pneumococcal polysaccharide vaccine (PPV23) and a protein conjugate pneumococcal vaccine (PCV13) are available in the United States. The former product contains capsular material from 23 pneumococcal serotypes; in the latter, capsular polysaccharide from 13 of the most frequent pneumococcal pathogens affecting children is linked to an immunogenic protein. PCV13 produces T cell\u2013dependent antigens that result in long-term immunologic memory. Administration of this vaccine to children has led to an overall decrease in the prevalence of antimicrobial-resistant pneumococci and in the incidence of invasive pneumococcal disease among both children and adults. However, vaccination can be followed by the replacement of vaccine serotypes with nonvaccine serotypes, as was seen with serotypes 19A and 35B after introduction of the original 7-valent conjugate vaccine. PCV13 now is also recommended for the elderly and for younger immunocompromised patients. Because of an increased risk of"
        },
        {
            "id": "Pediatrics_Nelson_2072",
            "title": "Pediatrics_Nelson",
            "content": "5. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6 weeks) Routine vaccination: \u007f Administer a Hib vaccine primary series and a booster dose to all infants. The primary series doses should be administered at 2, 4, and 6 months of age; however, if PRP-OMP (PedvaxHib or Comvax) is administered at 2 and 4 months of age, a dose at age 6 months is not indicated. One booster dose should be administered at age 12 through15 months. \u007f Hiberix (PRP-T) should only be used for the booster (final) dose in children aged 12 months through 4 years, who have received at least 1 dose of Hib. Catch-up vaccination: \u007f If dose 1 was administered at ages 12-14 months, administer booster (as final dose) at least 8 weeks after dose 1. \u007f If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax), and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose. \u007f If the first"
        },
        {
            "id": "Pediatrics_Nelson_2041",
            "title": "Pediatrics_Nelson",
            "content": "5. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6 weeks) Routine vaccination: \u007f Administer a Hib vaccine primary series and a booster dose to all infants. The primary series doses should be administered at 2, 4, and 6 months of age; however, if PRP-OMP (PedvaxHib or Comvax) is administered at 2 and 4 months of age, a dose at age 6 months is not indicated. One booster dose should be administered at age 12 through15 months. \u007f Hiberix (PRP-T) should only be used for the booster (final) dose in children aged 12 months through 4 years, who have received at least 1 dose of Hib. Catch-up vaccination: \u007f If dose 1 was administered at ages 12-14 months, administer booster (as final dose) at least 8 weeks after dose 1. \u007f If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax), and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose. \u007f If the first"
        },
        {
            "id": "Pediatrics_Nelson_2081",
            "title": "Pediatrics_Nelson",
            "content": "\u007f Administer 1 dose to persons aged 9 years and older. For children aged 6 months through 8 years: \u007f For the 2012\u201313 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. For additional guidance, follow dosing guidelines in the 2012 ACIP influenza vaccine recommendations, MMWR 2012; 61: 613\u2013618, available at http://www.cdc.gov/mmwr/pdf/wk/mm6132.pdf. \u007f For the 2013\u201314 season, follow dosing guidelines in the 2013 ACIP influenza vaccine recommendations."
        },
        {
            "id": "Pediatrics_Nelson_2050",
            "title": "Pediatrics_Nelson",
            "content": "\u007f Administer 1 dose to persons aged 9 years and older. For children aged 6 months through 8 years: \u007f For the 2012\u201313 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. For additional guidance, follow dosing guidelines in the 2012 ACIP influenza vaccine recommendations, MMWR 2012; 61: 613\u2013618, available at http://www.cdc.gov/mmwr/pdf/wk/mm6132.pdf. \u007f For the 2013\u201314 season, follow dosing guidelines in the 2013 ACIP influenza vaccine recommendations."
        },
        {
            "id": "InternalMed_Harrison_6472",
            "title": "InternalMed_Harrison",
            "content": "Infections with intracellular bacteria, fungi, parasites; virus reactivation a case-by-case basis following reevaluation.) aThe latest recommendations by the Advisory Committee on Immunization Practices and the CDC guidelines can be found at http://www.cdc.gov/vaccines. bA single dose of TDaP (tetanus\u2013diphtheria\u2013acellular pertussis), followed by a booster dose of Td (tetanus-diphtheria) every 10 years, is recommended for adults. cLive-virus vaccine is contraindicated; inactivated vaccine should be used. dTwo types of vaccine are used to prevent pneumococcal disease. A conjugate vaccine active against 13 serotypes (13-valent pneumococcal conjugate vaccine, or PCV13) is currently administered in three separate doses to all children. A polysaccharide vaccine active against 23 serotypes (23-valent pneumococcal polysaccharide vaccine, or PPSV23) elicits titers of antibody lower than those achieved with the conjugate vaccine, and immunity may wane more rapidly. Because the ablative"
        },
        {
            "id": "Pediatrics_Nelson_3431",
            "title": "Pediatrics_Nelson",
            "content": "Because greater than 80% of children less than 13 years of age with primary NS have steroid-responsive forms (chiefly MCNS), steroid therapy may be initiated without a renal biopsy if a child has typical features of NS. Typical therapy for MCNS is prednisone, 2 mg/kg/day (60 mg/m2/24 h, maximum 60 mg/day), provided once a day or split into multiple doses. Over 90% of children who respond to steroids do so within 4 weeks. Responders should receive steroids for 12 weeks. A renal biopsy is indicated for nonresponders because steroid resistance decreases the chance that MCNS is the underlying disease. Frequent relapses or steroid resistance may necessitate additional immunosuppressive therapy."
        },
        {
            "id": "Pediatrics_Nelson_2087",
            "title": "Pediatrics_Nelson",
            "content": "13. Meningococcal conjugate vaccines (MCV). (Minimum age: 6 weeks for Hib-MenCY, 9 months for Menactra [MCV4-D], 2 years for Menveo [MCV4-CRM]). Routine vaccination: \u007f Administer MCV4 vaccine at age 11\u201312 years, with a booster dose at age 16 years. \u007f Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV) infection should receive a 2-dose primary series of MCV4, with at least 8 weeks between doses. See MMWR 2011; 60:1018\u20131019 available at: http://www.cdc.gov/mmwr/pdf/wk/mm6030.pdf. \u007f For children aged 2 months through 10 years with high-risk conditions, see below. Catch-up vaccination: \u007f Administer MCV4 vaccine at age 13 through 18 years if not previously vaccinated. \u007f If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses. \u007f If the first dose is administered at age 16 years or older, a booster dose is not needed. \u007f For other catch-up"
        },
        {
            "id": "Pediatrics_Nelson_2056",
            "title": "Pediatrics_Nelson",
            "content": "13. Meningococcal conjugate vaccines (MCV). (Minimum age: 6 weeks for Hib-MenCY, 9 months for Menactra [MCV4-D], 2 years for Menveo [MCV4-CRM]). Routine vaccination: \u007f Administer MCV4 vaccine at age 11\u201312 years, with a booster dose at age 16 years. \u007f Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV) infection should receive a 2-dose primary series of MCV4, with at least 8 weeks between doses. See MMWR 2011; 60:1018\u20131019 available at: http://www.cdc.gov/mmwr/pdf/wk/mm6030.pdf. \u007f For children aged 2 months through 10 years with high-risk conditions, see below. Catch-up vaccination: \u007f Administer MCV4 vaccine at age 13 through 18 years if not previously vaccinated. \u007f If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses. \u007f If the first dose is administered at age 16 years or older, a booster dose is not needed. \u007f For other catch-up"
        },
        {
            "id": "Pediatrics_Nelson_2053",
            "title": "Pediatrics_Nelson",
            "content": "10. Varicella (VAR) vaccine. (Minimum age: 12 months) Routine vaccination: \u007f Administer the first dose of VAR vaccine at age 12 through 15 months, and the second dose at age 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid. Figure 94-1, cont\u2019d Catch-up vaccination: \u007f Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56 [No. RR-4], available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children aged 7 through 12 years the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks."
        },
        {
            "id": "Pediatrics_Nelson_2084",
            "title": "Pediatrics_Nelson",
            "content": "10. Varicella (VAR) vaccine. (Minimum age: 12 months) Routine vaccination: \u007f Administer the first dose of VAR vaccine at age 12 through 15 months, and the second dose at age 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid. Figure 94-2, cont\u2019d Catch-up vaccination: \u007f Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007;56 [No. RR-4], available at http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine. For children aged 7 through 12 years the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks."
        },
        {
            "id": "Pediatrics_Nelson_96",
            "title": "Pediatrics_Nelson",
            "content": "There is a growing body of evidence that notes that children who are in high quality early learning environments are more prepared to succeed in school. Every dollar invested in early childhood education may save taxpayers up to 13 dollars in future costs. These children commit fewer crimes and are better prepared to enter the workforce after school. Early Head Start (less than 3 years), Head Start (3 to 4 years), and prekindergarten programs (4 to 5 years) all demonstrate better educational attainment, although the earlier the start, the better the results. Readiness for preschool depends on the development of autonomy and the ability of the parent and the child to separate for hours at a time. Preschool experiences help children develop socialization skills; improve language; increase skill building in areas such as colors, numbers, and letters; and increase problem solving (puzzles)."
        },
        {
            "id": "Pediatrics_Nelson_322",
            "title": "Pediatrics_Nelson",
            "content": "Rarely children with insomnia are treated pharmacologically. Melatonin (dose, 2.5 to 10 mg) has soporific properties useful in treating delayed sleep phase syndrome. It has been used successfully in both children with normal development and those with developmental delays. Melatonin is available without prescription in stores that sell dietary supplements. The \u03b1-agonist clonidine acts preferentially on presynaptic \u03b12 neurons to inhibit noradrenergic activity. Somnolence is a side effect of clonidine, which can be put to use in cases of refractory sleep difficulties; this is an off-label use in children. Clonidine is usually started with a dose of 0.05 mg at bedtime and increased to 0.1 mg if needed. There are data on treating children as young as 4 years old with clonidine. Weaning offclonidine is recommended at the end of treatment."
        },
        {
            "id": "Pediatrics_Nelson_1859",
            "title": "Pediatrics_Nelson",
            "content": "of patients (15%) have type II disease, which is due to production of dysfunctional Cl-esterase inhibitor. A low C4 level serves as an initial screening test. Patients with reduced C4 should have quantitative and functional levels of Cl-esterase inhibitor measured. C2 levels are low during an acute attack. Type III HAE patients have normal laboratory evaluation. These patients are more typically females, but some males have been reported in the literature. Three products are approved to treat HAE attacks: Berinert (for acute facial or abdominal attacks in children \u226513 years old), Kalbitor (for acute attacks in children \u226516 years of age), and Cinryze (for prophylaxis in adolescents and adults)."
        },
        {
            "id": "InternalMed_Harrison_9781",
            "title": "InternalMed_Harrison",
            "content": "Since childhood vaccines have become widely available in the United States, major declines in rates of vaccine-preventable diseases among both children and adults have become evident (Table 148-2). For example, vaccination of children <5 years of age against seven types of Streptococcus pneumoniae led to a >90% overall reduction in invasive disease caused by those types. A series of childhood vaccines targeting 13 vaccine-preventable diseases in a single birth cohort leads to prevention of 42,000 premature deaths and 20 million illnesses and saves nearly $70 billion (U.S.). Control, Elimination, and Eradication of Vaccine-Preventable Diseases Immunization programs are associated with the goals of controlling,"
        },
        {
            "id": "InternalMed_Harrison_11660",
            "title": "InternalMed_Harrison",
            "content": "Polysaccharide\u2013Protein Conjugate Vaccines Infants and young children respond poorly to PPSV, which contains T cell\u2013independent antigens. Consequently, another class of pneumococcal vaccines, the PCVs, were developed specifically for infants and young children. The first product, a 7-valent PCV, was licensed in 2000 in the United States. Three PCV products\u2014containing 7, 10, and 13 serotypes, respectively\u2014are currently (2014) commercially available. The serotypes included in these PCV formulations are important causes of IPD and antibiotic resistance among young children. Randomized controlled trials have demonstrated a high degree of efficacy of PCVs against vaccine-serotype IPD as well as efficacy against pneumonia, otitis media, nasopharyngeal colonization, and all-cause mortality. PCVs are recommended by the World Health Organization for inclusion in routine childhood immu nization schedules worldwide, especially in countries with high infant mortality rates."
        },
        {
            "id": "Pediatrics_Nelson_2020",
            "title": "Pediatrics_Nelson",
            "content": "polysaccharide vaccine, as well. Children who are behind in immunization should receive catch-up immunizations as rapidly as feasible. Infants born prematurely, regardless of birth weight, should be vaccinated at the same chronologic age and according to the same schedule as full-term infants and children (see Fig. 94-2). The single exception to this practice is providing hepatitis B vaccine for infants weighing less than 2000 g if the mother is hepatitis B virus surface antigen (HBsAg)-negative at 1 month instead of at birth. Vaccines for adolescents should be given at 11 to 12 years of age (see Fig. 94-1), with completion of any vaccine series at 13 to 18 years of age and a booster for N. meningitidis at 16 years of age."
        },
        {
            "id": "Pediatrics_Nelson_2904",
            "title": "Pediatrics_Nelson",
            "content": "Delivering therapeutic agents to the lower respiratory tract can be accomplished by inhalation of aerosol forms of the agents via dry powder inhaler (DPI), metered dose inhaler (MDI), or nebulizer. All of these devices are designed to generate relatively small particles that can bypass the filtering action of the upper airway and deposit in the lower airways. Many factors influence drug deposition, including patient technique, device used, age of the child, and breathing pattern. Nebulizers should be used with a face mask (infants) or mouthpiece (children and teens) to minimize loss of drug to ambient air. Plastic holding chambers (spacers) are available for all ages and should always be used with MDIs. Dry powder inhalers require a single rapid deep inhalation for optimal drug delivery, which is difficult for children under 6 years of age. MDIs and nebulizers are equally effective in delivering medications only if the technique is correct, so it is important to review this frequently"
        },
        {
            "id": "Gynecology_Novak_1919",
            "title": "Gynecology_Novak",
            "content": "Figure 14.5 Foreign body (plastic toy) in the vagina of an 8-year-old girl. Figure 14.6 Straddle injury\u2014vulvar hematoma in a 13-year-old girl. Figure 14.7 Pelvic ultrasound (transabdominal) of a premenarchal 10-year-old girl. Diagnosis of Prepubertal Bleeding Hormonally active ovarian tumors can cause endometrial proliferation and bleeding. Likewise, exogenously administered estrogens can result in bleeding. Rarely, bleeding can result from the prolonged use of topical estrogens prescribed as therapy for vulvovaginitis or labial adhesions or from accidental ingestion of prescription estrogens."
        },
        {
            "id": "Pediatrics_Nelson_134",
            "title": "Pediatrics_Nelson",
            "content": "Children 3 Years of Age and Older"
        },
        {
            "id": "Pediatrics_Nelson_2359",
            "title": "Pediatrics_Nelson",
            "content": "Annual influenza vaccine is recommended for all children over 6 months of age (see Chapter 94). Trivalent, inactivated influenza vaccine is licensed for use beginning at 6 months of age; live, attenuated vaccine can be used for persons 2 to 49 years of age. Universal childhood vaccination with conjugate vaccines for H. influenzae type b and S. pneumoniae has greatly diminished the incidence of these pneumonias. The severity of RSV infections can be reduced by use of palivizumab in high-risk patients (see Chapter 109)."
        },
        {
            "id": "Gynecology_Novak_1914",
            "title": "Gynecology_Novak",
            "content": "Trauma (abuse, penetration) Figure 14.2 Urethral prolapse in prepubertal girl. Figure 14.3 Perianal condyloma in prepubertal girl. than age 6 years who have either breast development or pubic hair, rather than the traditional age of 8 (13). An expert panel concluded that there is reasonable evidence that pubertal milestones are occurring at a younger age in girls (3)."
        },
        {
            "id": "Pediatrics_Nelson_113",
            "title": "Pediatrics_Nelson",
            "content": "Percent of children passing 2550 75 90 (Check boxes for 1st, 2nd, or 3rd test) \u00a91969, 1989, 1990 W. K. Frankenburg and J. B. Dodds \u00a91978 W. K. Frankenburg \u00a92009 Wilhelmine R. Frankenburg Figure 8-1 Scoring form for Denver II. (From Frankenburg WK: Denver I Training Manual. \u00a91967, 1970 William K. Frankenburg and Josiah B. Dodds; 1975, 1976, 1978 William K. Frankenburg; 1990, 1992 William K. Frankenburg and Josiah B. Dodds; \u00a9 2009 Wilhelmine R. Frankenburg -Contact DDM, Inc. 1-800-419-4729 or Info@denverii.com.)"
        },
        {
            "id": "Pediatrics_Nelson_3559",
            "title": "Pediatrics_Nelson",
            "content": "trends of blood glucose concentrations but should not be used in calculations of mealtime insulin doses. Measurements of glycohemoglobin or hemoglobin A1c (HgbA1c) reflect the average blood glucose concentration over the preceding 3 months and provide a means for assessing long-term glycemic control. HgbA1c should be measured four times a year, and the results should be used for counseling of patients. The American Diabetes Association has set HgbA1c targets based on age with children less than 6 years having an HgbA1c target of 7.5% to 8.5%, ages 6 to 13 years HgbA1c target of less than 8%, and ages 13 to 18 years HgbA1c target of less than 7.5%. Measurements of HgbA1c are inaccurate in patients with hemoglobinopathies. Glycosylated albumin or fructosamine can be used in these cases."
        },
        {
            "id": "Immunology_Janeway_1818",
            "title": "Immunology_Janeway",
            "content": "In DN3 thymocytes (see Fig. 8.18), the expressed \u03b2 chains pair with a surrogate pre-T-cell receptor \u03b1 chain called pT\u03b1 (pre-T-cell \u03b1), which allows the assembly of a complete pre-T-cell receptor (pre-TCR) that is analogous in structure and function to the pre-B-cell receptor. The pre-TCR is expressed on the cell surface in a complex with the CD3 molecules that provide the signaling components of T-cell receptors (see Section 7-7). As with the preB-cell receptor, the assembly of the CD3:pre-T-cell receptor complex causes constitutive signaling that does not require interaction with a ligand. Recent structural evidence shows that the pre-TCR forms dimers in a manner similar to pre-BCR dimerization. The pT\u03b1 Ig domain makes two important contacts. It associates with the constant-region Ig domain of the V\u03b2subunit to form the pre-TCR itself. A distinct surface of the pre-T\u03b1 then binds to a V\u03b2 domain from another pre-TCR molecule, forming a bridge between two different pre-TCRs. The region"
        },
        {
            "id": "Pediatrics_Nelson_2030",
            "title": "Pediatrics_Nelson",
            "content": "Range of recommended ages during which ages for all children Range of recommended Range of recommended ages Range of recommended ages for Not routinely recommended high-risk groups catch-up is encouraged and for certain for catch-up immunization certain high-risk groups"
        },
        {
            "id": "Pharmacology_Katzung_5500",
            "title": "Pharmacology_Katzung",
            "content": "The presence of baseline NS5A resistance-associated variants (RAVs) significantly reduced rates of SVR at 12 weeks using elbasvir/grazoprevir regimen in patients with genotype 1a. Since 10\u201315% of patients without prior exposure will have NS5A RAVs, baseline testing should be considered prior initiation of therapy. Absorption is not food-dependent. Peak concentrations after ingestion occur at a median of 3 hours. Elbasvir is extensively bound to plasma proteins (>99.9%), partially eliminated by oxidative metabolism, and primarily excreted in the feces. Elbasvir/ grazoprevir should not be administered to patients with moderate or severe hepatic impairment or in conjunction with organic anion transporting polypeptides 1B1/3 (OATP1B1/3) inhibitors, strong inducers or inhibitors of CYP3A, or efavirenz. The most commonly reported side effects during therapy with elbasvir/grazoprevir were fatigue, headache, and nausea. Elevations in serum aminotransferases may occur."
        },
        {
            "id": "First_Aid_Step2_1327",
            "title": "First_Aid_Step2",
            "content": "content. The last chapter in-cludes excellent vignette-based questions. Offers thorough, wellwritten explanations. Includes a nice primer on test-taking strategies. Cons: Non-vignette-based questions are shorter and more straightfor-ward than those on the Step 2 CK exam. Some questions may be too detailed for Step 2 CK preparation. Poorly illustrated. Summary: An excellent, concise review with appropriate content and good discus-sions, but the majority of questions do not re\ufb02ect Step 2 CK style. $41.95 Test/1000+ q B\u2212NMS Pediatrics DWORKIN Lippincott Williams & Wilkins, 2008, 5th ed., 480 pages, ISBN 9780781770750 A general review of pediatrics in outline format. Includes questions at the end of each chapter. Pros: A thorough, detailed review of pediat-rics. Boldfacing highlights key points. Case studies and a comprehen-sive exam at the end of the book (also provided on CD-ROM) are helpful. Includes a good discussion. Cons: A dense, lengthy text. Lacks good illustrations of any kind."
        }
    ],
    "scores": [
        0.02430470718729075,
        0.02142804004506132,
        0.021350762527233117,
        0.01906318082788671,
        0.01739656606913244,
        0.016946778711484593,
        0.016800936445637953,
        0.01552868658131816,
        0.015498373262348417,
        0.015395731436193865,
        0.01492921492921493,
        0.014843410178338408,
        0.014819237867766802,
        0.014150487781319424,
        0.014047619047619048,
        0.014043559672809697,
        0.013678804855275443,
        0.013458110516934046,
        0.012286586514905967,
        0.012038205081996756,
        0.011532343584305408,
        0.010336538461538461,
        0.009900990099009901,
        0.009900990099009901,
        0.009900990099009901,
        0.00980392156862745,
        0.00980392156862745,
        0.009708737864077669,
        0.009708737864077669,
        0.009708737864077669,
        0.009615384615384616,
        0.009615384615384616
    ]
}